Altimmune, Inc. (NASDAQ:ALT) CFO Buys $52,000.00 in Stock

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CFO Gregory L. Weaver bought 10,000 shares of Altimmune stock in a transaction on Thursday, March 13th. The stock was acquired at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Altimmune Stock Down 6.0 %

ALT traded down $0.36 during trading on Tuesday, reaching $5.61. 2,528,672 shares of the stock traded hands, compared to its average volume of 3,009,963. The stock's 50-day moving average is $6.45 and its 200 day moving average is $7.11. Altimmune, Inc. has a 12 month low of $5.14 and a 12 month high of $11.16. The stock has a market capitalization of $432.05 million, a PE ratio of -3.62 and a beta of 0.87.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. As a group, equities research analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current year.

Remove Ads

Institutional Trading of Altimmune

Several large investors have recently modified their holdings of ALT. Sunbelt Securities Inc. lifted its position in shares of Altimmune by 356.8% during the 4th quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company's stock valued at $79,000 after acquiring an additional 8,470 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Altimmune by 16.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,392 shares of the company's stock worth $666,000 after purchasing an additional 13,126 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of Altimmune by 33.2% during the 4th quarter. Two Sigma Investments LP now owns 605,303 shares of the company's stock worth $4,364,000 after purchasing an additional 151,001 shares in the last quarter. Rafferty Asset Management LLC grew its stake in shares of Altimmune by 1.3% in the 4th quarter. Rafferty Asset Management LLC now owns 157,750 shares of the company's stock valued at $1,137,000 after buying an additional 1,964 shares during the period. Finally, ProShare Advisors LLC increased its position in Altimmune by 74.1% in the 4th quarter. ProShare Advisors LLC now owns 23,371 shares of the company's stock valued at $169,000 after buying an additional 9,950 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ALT. William Blair reiterated a "market perform" rating on shares of Altimmune in a research note on Friday. HC Wainwright reissued a "buy" rating and set a $12.00 price target on shares of Altimmune in a research note on Tuesday. Finally, Stifel Nicolaus began coverage on Altimmune in a research note on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.83.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.